Health Care Equipment

SINOMED

SINOMED released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 139.74 M, actual EPS CNY 0.06

SINOMED to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

SINOMED to release FY2025 earnings on March 26 Pre-Market (BJT), forecast revenue CNY 577 M, EPS CNY 0.04

SINOMED released FY2025 annual earnings on February 25 Pre-Market (BJT), actual revenue CNY 525.41 M (forecast CNY 577 M), actual EPS CNY 0.11 (forecast CNY 0.04)

SINOMED released FY2025 Q4 earnings on February 25 Pre-Market (BJT), actual revenue CNY 161.55 M, actual EPS CNY 0.0578

SINOMED released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 363.85 M, actual EPS CNY 0.0485

SINOMED released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 123.38 M, actual EPS CNY 0.0211

SINOMED FY2025 Q3 Earnings Release on October 31, Pre-Market BJT

SINOMED released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 240.48 M, actual EPS CNY 0.03

SINOMED released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 139.63 M, actual EPS CNY 0.0173

SINOMED to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Director of Sino Medical Reduced Shares

Sinomed Responds to Investors About R&D and Product Approval Milestones in 2025

SinoShenchang Medical Technology Obtains Registration Certificate for Flow Diverting Stent

Sinomed's Two Coronary Balloon Dilatation Catheters Approved in Mexico and Ecuador

Sinuo Medical Reports Significant Profit Growth in 2024

SINOMED released FY2025 Q1 earnings on April 25 During-Market (BJT), actual revenue CNY 100.85 M, actual EPS CNY 0.01

SINOMED FY2025 Q1 Earnings Release on April 26 During-Market BJT

SINOMED to release FY2024 earnings on April 26 After-Market BJT, forecast revenue CNY 475 M, EPS CNY 0.03

SINOMED released FY2024 Q4 earnings on February 26 After-Market (BJT), actual revenue CNY 140.25 M, actual EPS CNY 0.0305

LABU

IBBQ

ARKG

A new study, the EXCEL clinical trial, has shown that treatment with essential phospholipids (Essentiale) leads to a 2.5 times greater reduction in liver fat and significant improvements in fatigue and glycaemic control in patients with Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD), compared to diet and exercise alone. This groundbreaking research highlights the importance of early intervention and effective treatment options for the millions affected by this prevalent chronic liver disease.

prnewswire

Sanofi

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Health Care Select Sector SPDR

VG Health

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

07:13 ETThe EXCEL - First-of-its-kind study highlights critical role of essential phospholipids in improving Fatty Liver Disease

159837

159849

516820

688108

688480

588860

Sanofi's investigational therapy Lunsekimig has shown promise in treating chronic respiratory diseases, meeting primary and key secondary endpoints in two Phase 2 studies. The AIRCULES study demonstrated significant reductions in asthma exacerbations and improved lung function in adults with moderate-to-severe asthma. The DUET study showed improvements in nasal congestion and polyp scores in patients with chronic rhinosinusitis with nasal polyps. Lunsekimig targets two inflammatory drivers, TSLP and IL-13, and was well tolerated. Sanofi plans further studies and will present detailed results at upcoming medical congresses.

nasdaq

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

iShares Global Healthcare

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Direxion S&P Biotech Bear 3X

ChinaAMC SSE STAR Biology and Medicine ETF

Banco Santander SA-Spon

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Sanofi's Lunsekimig Shows Promise In Respiratory Diseases

513060

588250

159316

Sanofi has received conditional marketing authorization from the European Commission for Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 and older with a minimum weight of 40 kg. This authorization is contingent on completing a confirmatory study. The approval follows a positive opinion from the CHMP and is based on safety and efficacy results from clinical studies. Rezurock is also approved in 20 other countries. Sanofi shares closed at 81.90 euros, down 0.11%.

rttnews

Bosera Hang Seng Health Care ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock

SINOMED: Planning to issue H-shares and list on The Stock Exchange of Hong Kong Limited

Wallstreetcn

159892

Sanofi's Sarclisa subcutaneous injector for multiple myeloma received a positive recommendation from the EMA CHMP, with EU decision pending and FDA review ongoing. Dupixent was approved in Japan for adults with moderate-to-severe bullous pemphigoid, showing promising trial results. However, Sanofi's late-stage IL-33 COPD trial failed to meet its primary endpoints, contrasting with positive data from competitors.

TradingView

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails

02269

Earendil Labs, an AI-driven biotechnology company, has raised $787 million in financing to enhance its biologics discovery and development. The funding, supported by global investors including Sanofi and Dimension Capital, will accelerate the company's AI-driven R&D platform and expand its pipeline of antibody programs. The CEO emphasized AI's role in advancing therapeutic programs, with plans for multiple clinical developments. The investment aims to translate AI innovation into transformative medicines for patients with serious diseases, while strengthening strategic partnerships to enhance research and development efforts globally.

WUXI BIO

Eledon Pharmaceuticals

WuXi Biologics

07:30 ETEarendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

Biotechnology startup Earendil Labs plans to go public in Hong Kong, aiming to raise up to $500 million (approximately HKD 3.9 billion). The company has partnerships with well-known pharmaceutical companies such as Sanofi and WuXi Biologics. Meanwhile, integrated circuit design company Guomin Technology and network solutions provider Feisuke Innovation have also begun their initial public offerings, planning to raise HKD 1.03 billion and HKD 1.66 billion, respectively, with strong oversubscription performance on their first day

Stheadline

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

WUXI APPTEC

WuXi AppTec

Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec

SINOMED(688108.SH)